Food Structure and Satiety

Summary

Based on in vitro studies identifying changes in food structures potential to delay digestion as well as results from animal studies showing potential of these foods to decrease appetite, nano-particulated whey protein and high molecular weight whey protein-alginate coacervates were chosen to be investigated in humans. Thereby, the aim of this short-term study is to investigate if nano-particulated whey protein has appetite reducing effects in humans compared to non-particulated whey protein (Part 1) as well as if high molecular weight whey protein-alginate coacervates have appetite reducing effects in humans compared to calcium alginate (Part 2).

Conditions

• Appetitive Behavior

Interventions

COMBINATION_PRODUCT

Nano-particulated whey protein vs non-particulated whey protein (control)

Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.

COMBINATION_PRODUCT

High molecular weight whey protein-alginate coacervates vs calcium alginate (control)

Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.

Sponsors & Collaborators

• University of Copenhagen

  collaborator OTHER

• Technical University of Denmark

  collaborator OTHER

• DuPont Nutrition and Health

  collaborator INDUSTRY

• Arla Foods

  collaborator INDUSTRY

• Arne Astrup

  lead OTHER

Principal Investigators

• Anders Sjödin, PhD · University of Copenhagen, Department of Nutrition, Exercise and Sports

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

45 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-04-25

Primary Completion

2020-06-30

Completion

2020-06-30

Countries

• Denmark

Study Locations